Provita Sp. z o.o.
- Address
- Ul. Fabryczna 15b, 40-611 Katowice, Poland
Immune System Diseases Research
The Dermatology Department at Provita Sp. z o.o. is focused on immune‑mediated conditions such as Alopecia Areata, Allergic Rhinitis/Rhinoconjunctivitis triggered by house dust mite, and Hidradenitis Suppurativa. Current studies aim to evaluate new therapies that can reduce disease activity and improve patient quality of life.
- Assessing oral JAK inhibitor upadacitinib for severe alopecia areata
- Evaluating subcutaneous immunotherapy for dust‑mite induced allergic rhinitis
- Testing biologic agent izokibep in hidradenitis suppurativa
Provita Sp. z o.o., located in Katowice, Poland, is conducting five clinical trials with a team of seven investigators, all within the immune‑system disease therapeutic area.
Skin and Connective Tissue Diseases Research
In the field of Skin and Connective Tissue Diseases, the department investigates disorders that affect the skin’s appearance and function, including Plaque Psoriasis, Hidradenitis Suppurativa, and Alopecia Areata. The primary goal of these trials is to test innovative treatments that target inflammation and promote skin healing.
- Investigating DC‑806 for moderate to severe plaque psoriasis
- Studying izokibep in patients with hidradenitis suppurativa
- Exploring upadacitinib’s impact on skin manifestations of alopecia areata
The Dermatology Department at Provita Sp. z o.o. currently manages five clinical studies, employing seven investigators to advance therapeutic options for skin and connective tissue diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 90 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 90 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Pfizer Inc.5active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.9trials
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Provita Sp. z o.o.
lock Showing 1 of 75 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 90 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 5 | Unknown | 2022-11-10 | 2024-10-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.